An Empirical Assay For Assessing Genomic Sensitivity And For Improving Cancer Diagnostics | 73257
Journal of Cancer Science & Therapy
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Detection tests have been developed for many cancers, but there is no single test to identify cancer in general. We have
developed such an assay. In this modified patented Comet assay, we investigated peripheral lymphocytes of 208 individuals:
20 melanomas, 34 colon cancers, 4 lung cancer patients, 18 suspect melanomas, 28 polyposis, 10 COPD patients and 94 healthy
volunteers. The natural logarithm of the olive tail moment was plotted for exposure to UVA through different agar depths for
each of the above groups and analyzed using a repeated measures regression model. Response patterns for cancer patients
formed a plateau after treating with UVA where intensity varied with different agar depths. In comparison, response patterns
for healthy individuals returned towards control values and for pre/suspected cancers, were intermediate with less of a plateau.
All cancers tested exhibited comparable responses. Analyses of receiver operating characteristic curves, of mean log olive
tail moments, for all cancers plus pre/suspected-cancer versus controls gave a value for the area under the curve of 0.87; for
cancer versus pre/suspected-cancer plus controls the value was 0.89; and for cancer alone versus controls alone (excluding pre/
suspected-cancer), the value was 0.93. By varying the threshold for test positivity, its sensitivity or specificity can approach
100% whilst maintaining acceptable complementary measures. Evidence presented indicates that this modified assay shows
promise as both a stand-alone test and as a possible adjunct to other investigative procedures, as part of detection programs
for a range of cancers.
Diana Anderson holds the Established Chair position in Biomedical Sciences at the University of Bradford. She has obtained her first degree in the University of Wales and second degree in the Faculty of Medicine, University of Manchester. She has 450+ peer-reviewed papers, 9 books, has successfully supervised 29 PhDs, and been a Member of Editorial Boards of 10 international journals. She has been or is Editor in Chief of a book series on Toxicology for J Wiley and Sons and the Royal Society of Chemistry respectively. She gives key note addresses at various international meetings. She is a consultant for many international organizations, such as the WHO, NATO, TWAS, UNIDO and the OECD. Her h index = 54.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals